Identification of pathogenic GCK variants in patients with common type 2 diabetes can lead to discontinuation of pharmacological treatment.
Thuesen ACB, Jensen RT, Maagensen H, Kristiansen MR, Sørensen HT, Vaag A, Beck-Nielsen H, Pedersen OB, Grarup N, Nielsen JS, Rungby J, Gjesing AP, Storgaard H, Vilsbøll T, Hansen T.
Thuesen ACB, et al. Among authors: maagensen h.
Mol Genet Metab Rep. 2023 Mar 29;35:100972. doi: 10.1016/j.ymgmr.2023.100972. eCollection 2023 Jun.
Mol Genet Metab Rep. 2023.
PMID: 37008541
Free PMC article.